2. 您的位置
3. 首页
4. 会议论文
5. Consolidation Chemotherapy may Improve Survival for Patients with Locally Advanced Non-small-cell Lu

Consolidation Chemotherapy may Improve Survival for Patients with Locally Advanced Non-small-cell Lu

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户：hawk1918

【摘 要】

：

Objective: For patients with locally advanced non-small-cell lung cancer (LA-NSCLC), the role of consolidation chemotherapy (CCT) following concurrent chemoradiotherapy (CRT) is partially defined.

【作 者】

：

Lipin Liu Nan Bi Zhe Ji Junling Li Jingbo Wang Xiaozhen Wang Zhouguang Hui Jima Lv Jun Liang Zongmei Zhou Yan Wang Weibo Yin Luhua Wang 

【机 构】

：

Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences

【出 处】

：

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会

【发表日期】

：

2015年4期

【关键词】

：

Locally advanced non-small-cell lung cancer Consol 

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　Objective: For patients with locally advanced non-small-cell lung cancer (LA-NSCLC), the role of consolidation chemotherapy (CCT) following concurrent chemoradiotherapy (CRT) is partially defined.

其他文献

动态监测131I治疗前刺激性Tg在分化型甲状腺癌远处转移诊治中的增益效应

目的：探讨动态监测131I治疗前刺激性甲状腺球蛋白(preablative stimulated thyroglobulin,ps-Tg)变化在伴有远处转移的分化型甲状腺癌(differentiated thyroid cancer,DTC)诊治中的意义。方法：317例甲状腺全切或次全切术后拟行131I治疗的DTC患者,根据是否存在远处转移(distant metastasis,DM)分为M1组(

会议

分化型甲状腺癌甲状腺球蛋白131I治疗

分化型甲状腺癌侵犯喉气管20例临床分析

目的：探讨甲状腺癌累及喉、气管时的外科处理。方法：2000-2010年我院手术治疗晚期分化型甲状腺癌20例，根据分化型甲状腺癌侵犯喉、颈段气管的范围及程度行肿瘤削除术、气管楔形切除缝合术、气管窗状切除胸锁乳突肌肌骨膜瓣修复术、气管袖状切除端端吻合术、气管袖状切除游离前臂皮瓣气管重建术；全喉切或近全切除术。

会议

甲状腺癌外科治疗

Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent SCLC:CA209-032 (N

Objective: Patients (pts) with SCLC respond to initial platinum (PLT) based chemotherapy (CT), but rapidly progress.Combined blockade of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4

会议

nivolumabipilimumabsmall cell lung cancer

Erlotinib as Neoadjuvant Treatment in Endobronchial Ultrasound Confirmed Stage ⅢA-N2 Non-small Cell

Background: Concurrent chemoradiation therapy or induction chemotherapy plus surgery were considered as standard treatment to non-small-cell lung cancer (NSCLC) in stage ⅢA-N2, but the side effect bec

会议

NSCLC

18F-FDG PET maximal standardized uptake and serum CEA levels before initial treatment are associated

Objective: Several phase Ⅲ studies demonstrated that, compared with traditional chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), as first-linetreatments, contribu

会议

NSCLCEGFR-TKIserum CEA

Survival analysis of non-small cell lung cancer using TKI treatment-- A multi-center retrospective s

Objective: To assess differences in overall survival among patients with NSCLC using TKIs in first or second line treatment and different TKIs.Method: Collecting patients data in CRF and use SPSS soft

会议

lung cancerTyrosine kinase inhibitorSurvival ana

Efficacy and safety of nitroglycerin combined with chemotherapy in the elderly patients with advance

Objective: To investigate the efficacy and safety of the treatment of nitroglycerin combined with docetaxel/carboplatin chemotherapy for the elderly patients with advanced non-small cell lung cancer (

会议

Geriatric OncologyNSCLCNitroglycerin

消癌平注射液改善非小细胞肺癌细胞对gefitinib和erlotinib双重耐药的作用及机理

目的：通过吉非替尼(gefitinib)和厄洛替尼(erlotinib)双重耐药非小细胞肺癌(NSCLC)细胞HCC827/ER研究消癌平注射液(XAP)改善gefitinib和erlotinib耐药的作用及机理。方法：通过erlotinib 长期诱导形成耐药细胞株HCC827/ER,MTT检测细胞增殖,Taqman探针实时荧光定量PCR检测Met基因拷贝数,Western blot法检测细胞蛋白

会议

非小细胞肺癌消癌平注射液gefitinib和erlotinib双重耐药

Identifying the Role of Protein kinase CK2 in the Radiosensitivity of Non-small Cell Lung Cancer

Objective: Proteinkinase CK2 (also known ascasein kinase) is a highlyconserved seine/threonine protein kinase, which is ubiquitously expressed inmammalian cells.CK2 has been implicated in multiple phy

会议

Protein kinase CK2RadiosensitivityNon small cell

Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma

Objective: Stem-like cells in solid tumors are purported to contribute to cancer development and poor treatment outcome.The abilities to self-renew, differentiate, and resist anticancer therapies are

会议

lung cancerstem cellvitamin D